Royal Bank of Canada decreased its stake in shares of Ventas, Inc. (NYSE:VTR – Free Report) by 38.0% in the 1st quarter, Holdings Channel reports. The fund owned 540,916 shares of the real estate investment trust’s stock after selling 331,837 shares during the quarter. Royal Bank of Canada’s holdings in Ventas were worth $44,237,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in VTR. Dynamic Wealth Strategies LLC bought a new stake in shares of Ventas in the first quarter valued at about $25,000. Wiser Advisor Group LLC bought a new position in shares of Ventas during the third quarter worth about $27,000. IFC & Insurance Marketing Inc. acquired a new stake in Ventas in the 4th quarter valued at approximately $30,000. Elyxium Wealth LLC acquired a new stake in Ventas in the 4th quarter valued at approximately $33,000. Finally, Reflection Asset Management bought a new stake in Ventas in the 4th quarter valued at approximately $34,000. 94.18% of the stock is currently owned by institutional investors and hedge funds.
Ventas Stock Performance
Shares of VTR opened at $93.94 on Monday. The company has a market cap of $45.67 billion, a PE ratio of 173.96, a price-to-earnings-growth ratio of 2.01 and a beta of 0.69. The firm has a 50-day moving average of $88.99 and a 200-day moving average of $85.65. Ventas, Inc. has a one year low of $65.82 and a one year high of $101.60. The company has a debt-to-equity ratio of 0.86, a current ratio of 0.44 and a quick ratio of 0.44.
Ventas Dividend Announcement
Insider Activity at Ventas
In other Ventas news, Director Michael J. Embler bought 2,500 shares of Ventas stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $78.81 per share, for a total transaction of $197,025.00. Following the purchase, the director owned 19,202 shares of the company’s stock, valued at $1,513,309.62. The trade was a 14.97% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Walter C. Rakowich sold 1,152 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $90.20, for a total value of $103,910.40. Following the transaction, the director directly owned 28,349 shares in the company, valued at $2,557,079.80. The trade was a 3.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.53% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
VTR has been the subject of a number of recent research reports. Cantor Fitzgerald upped their price target on Ventas from $97.00 to $102.00 and gave the stock an “overweight” rating in a research report on Friday. Barclays began coverage on shares of Ventas in a report on Tuesday, July 7th. They set an “equal weight” rating and a $99.00 target price for the company. Mizuho lifted their price target on shares of Ventas from $98.00 to $104.00 and gave the company an “outperform” rating in a research note on Wednesday, July 22nd. Royal Bank Of Canada boosted their price target on shares of Ventas from $91.00 to $98.00 and gave the stock an “outperform” rating in a research report on Monday, May 4th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Ventas from $93.00 to $94.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Ventas presently has a consensus rating of “Moderate Buy” and an average price target of $97.00.
Get Our Latest Research Report on VTR
About Ventas
Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.
Ventas’ business model combines property ownership with active asset management and capital markets activity.
Featured Articles
- Five stocks we like better than Ventas
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Want to see what other hedge funds are holding VTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventas, Inc. (NYSE:VTR – Free Report).
Receive News & Ratings for Ventas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventas and related companies with MarketBeat.com's FREE daily email newsletter.
